Doctor Alexander Michel
Bayer AG, Basel (Switzerland)
Follow
Contributor content
Presentation
Clinical characteristics and outcomes in a cohort of patients starting treatment with vericiguat in the US.
Presentation
Factors influencing the up-titration to 10 mg target dose of vericiguat: data from a large observational cohort-study in the US.
Presentation
Length of hospital stay, re-hospitalization rates and comorbidities in patients with worsening heart failure. Data from 3 large cohort studies in the US, Germany and Japan.
Presentation
Real-world analysis of heart failure medication before and after hospitalization for heart failure. Data from two large cohorts in the US and Germany.
Presentation
Persistence to guideline-based therapy newly prescribed after a hospitalization for heart failure. Data from two large cohorts in the US and Germany.
Presentation
Risk of first ischemic cerebrovascular event in a cohort of incident heart failure patients
Presentation
